| Recruitment status | Terminated |
| Unique ID issued by UMIN | UMIN000018553 |
| Receipt No. | R000021399 |
| Official scientific title of the study | Efficiency of insulin-like growth factor 1 therapy for cerebral ischemia by cardiopulmonary arrest |
| Date of disclosure of the study information | 2015/10/01 |
| Last modified on | 2016/04/02 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | Efficiency of insulin-like growth factor 1 therapy for cerebral ischemia by cardiopulmonary arrest | |
| Title of the study (Brief title) | Efficiency of IGF-1 therapy for cerebral ischemia by CPA | |
| Region |
|
|
| Condition | |||
| Condition | Cerebral ischemia by cardiopulmonary arrest | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | Efficiency of insulin-like growth factor 1 therapy for cerebral ischemia by cardiopulmonary arrest |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | Inhospital mortality |
| Key secondary outcomes | Neurologic outcome |
| In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | insulin-like growth factor 1 | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required. |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | cardiopulmonary arrest | |||
| Key exclusion criteria | trauma | |||
| Target sample size | 30 | |||
| Research contact person | |
| Name of lead principal investigator | Naoya Matsuda |
| Organization | Yokohama City Minato Red Cross Hospital |
| Division name | Emergency and critical care center |
| Address | 3-12-1 Shinyamashita, Naka-ku, Yokohama city, Japan |
| TEL | 045-628-6100 |
| n.matsuda.shinshu@gmail.com | |
| Public contact | |
| Name of contact person | Naoya Matsuda |
| Organization | Yokohama City Minato Red Cross Hospital |
| Division name | Emergency and critical care center |
| Address | 3-12-1 Shinyamashita, Naka-ku, Yokohama city, Japan |
| TEL | 045-628-6100 |
| Homepage URL | |
| n.matsuda.shinshu@gmail.com | |
| Sponsor | |
| Institute | Emergency and critical care center |
| Institute | |
| Department | |
| Sponsor means an organization that is responsible for plan, deployment and report of the research including funding management. It doesn't mean funding agency". Therefore, all clinical trial should have the one. |
| Funding Source | |
| Organization | TEIJIN Pharma |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 横浜市立みなと赤十字病院(神奈川県) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Terminated | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-bin/icdr_e/ctr_view.cgi?recptno=R000021399 |